Cargando…

Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives

CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) are functionally distinct subsets of mature T cells with broad suppressive activity and have been shown to play an important role in the establishment of immune tolerance after allogeneic hematopoietic stem cell transplantation (HSCT). Tregs exhibit a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikegawa, Shuntaro, Matsuoka, Ken-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435715/
https://www.ncbi.nlm.nih.gov/pubmed/34526990
http://dx.doi.org/10.3389/fimmu.2021.713358
_version_ 1783751855461892096
author Ikegawa, Shuntaro
Matsuoka, Ken-ichi
author_facet Ikegawa, Shuntaro
Matsuoka, Ken-ichi
author_sort Ikegawa, Shuntaro
collection PubMed
description CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) are functionally distinct subsets of mature T cells with broad suppressive activity and have been shown to play an important role in the establishment of immune tolerance after allogeneic hematopoietic stem cell transplantation (HSCT). Tregs exhibit an activated phenotype from the stage of emigration from the thymus and maintain continuous proliferation in the periphery. The distinctive feature in homeostasis enables Tregs to respond sensitively to small environmental changes and exert necessary and sufficient immune suppression; however, on the other hand, it also predisposes Tregs to be susceptible to apoptosis in the inflammatory condition post-transplant. Our studies have attempted to define the intrinsic and extrinsic factors affecting Treg homeostasis from the acute to chronic phases after allogeneic HSCT. We have found that altered cytokine environment in the prolonged post-HSCT lymphopenia or peri-transplant use of immune checkpoint inhibitors could hamper Treg reconstitution, leading to refractory graft-versus-host disease. Using murine models and clinical trials, we have also demonstrated that proper intervention with low-dose interleukin-2 or post-transplant cyclophosphamide could restore Treg homeostasis and further amplify the suppressive function after HSCT. The purpose of this review is to reconsider the distinctive characteristics of post-transplant Treg homeostasis and discuss how to harness Treg homeostasis to optimize posttransplant immunity for developing a safe and efficient therapeutic strategy.
format Online
Article
Text
id pubmed-8435715
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84357152021-09-14 Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives Ikegawa, Shuntaro Matsuoka, Ken-ichi Front Immunol Immunology CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) are functionally distinct subsets of mature T cells with broad suppressive activity and have been shown to play an important role in the establishment of immune tolerance after allogeneic hematopoietic stem cell transplantation (HSCT). Tregs exhibit an activated phenotype from the stage of emigration from the thymus and maintain continuous proliferation in the periphery. The distinctive feature in homeostasis enables Tregs to respond sensitively to small environmental changes and exert necessary and sufficient immune suppression; however, on the other hand, it also predisposes Tregs to be susceptible to apoptosis in the inflammatory condition post-transplant. Our studies have attempted to define the intrinsic and extrinsic factors affecting Treg homeostasis from the acute to chronic phases after allogeneic HSCT. We have found that altered cytokine environment in the prolonged post-HSCT lymphopenia or peri-transplant use of immune checkpoint inhibitors could hamper Treg reconstitution, leading to refractory graft-versus-host disease. Using murine models and clinical trials, we have also demonstrated that proper intervention with low-dose interleukin-2 or post-transplant cyclophosphamide could restore Treg homeostasis and further amplify the suppressive function after HSCT. The purpose of this review is to reconsider the distinctive characteristics of post-transplant Treg homeostasis and discuss how to harness Treg homeostasis to optimize posttransplant immunity for developing a safe and efficient therapeutic strategy. Frontiers Media S.A. 2021-08-30 /pmc/articles/PMC8435715/ /pubmed/34526990 http://dx.doi.org/10.3389/fimmu.2021.713358 Text en Copyright © 2021 Ikegawa and Matsuoka https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ikegawa, Shuntaro
Matsuoka, Ken-ichi
Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives
title Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives
title_full Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives
title_fullStr Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives
title_full_unstemmed Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives
title_short Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives
title_sort harnessing treg homeostasis to optimize posttransplant immunity: current concepts and future perspectives
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435715/
https://www.ncbi.nlm.nih.gov/pubmed/34526990
http://dx.doi.org/10.3389/fimmu.2021.713358
work_keys_str_mv AT ikegawashuntaro harnessingtreghomeostasistooptimizeposttransplantimmunitycurrentconceptsandfutureperspectives
AT matsuokakenichi harnessingtreghomeostasistooptimizeposttransplantimmunitycurrentconceptsandfutureperspectives